Principal Analyst, Datamonitor Healthcare
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Amanda Micklus
Allergan signed an $800m deal to investigate Exicure's Spherical Nucleic Acid (SNA) gene regulation and immune modulation technology for the treatment of hair loss. Novartis invested in cardiology through the $9.7bn acquisition of The Medicines Co. Biopharma financing greatly increased due to the $30bn notes offering done by AbbVie to fund part of the Allergan deal.
Device financing increased substantially in Q3, thanks to debt raises led by Insulet. Acquisition dollar volume dropped, though, but Siemens' buy of Corindus for $1.1bn was a stand-out. Diagnostics/research tools financing dropped by 28% from Q2, while acquisition value greatly increased due to Exact Sciences' $2.8bn purchase of Genomic Health.
BeiGene gained rights to three Amgen drugs in China in a deal worth $1.25bn, while Amgen took a $2.7bn stake in BeiGene. Nestle Skin Health was spun out as Galderma and sold to private equity for $10bn. Biopharma financing maintained the levels seen in previous months, but device funding was down.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November 2019.